Shorted
Prescient Therapeutics logo
PTX
Pharmaceuticals, Biotechnology & Life Sciences

Prescient Therapeutics

Short interest
<0.01%
0.00 pp 30d
as of 14 Apr 2026
Reported shorts
11K
Shares on issue
1.052B

Prescient Therapeutics (PTX) company profile

Profile, insiders and operations

Company

AI-generated research profile of Prescient Therapeutics

pharmaceuticals
oncology
targeted therapy
cell therapies
clinical stage

Prescient Therapeutics is a clinical-stage oncology company focused on developing targeted therapies for cancer treatment. Their business model centers around advancing a diversified pipeline of assets, including PTX-100 in Phase 2a clinical development, and next-generation cell therapy platforms like OmniCAR and CellPryme, sourced from collaborations with leading research institutions.

Director trades

20 trades recorded

DateDirectorTypeSharesPriceValue
2026-10-06Unknown Director
buy
---
2026-10-06Unknown Director
buy
---
2026-10-06Unknown Director
buy
---
2026-09-30Melanie Farris
buy
76,923--
2026-09-30Gavin Shepherd
buy
200,000--
2026-09-30James Campbell
buy
153,846--
2025-11-21Unknown Director
buy
---
2025-11-21Unknown Director
buy
---
2025-11-21Unknown Director
buy
---
2025-11-21Unknown Director
buy
---
2025-11-21Unknown Director
buy
---
2025-11-18Ellen Gwen Feigal
other
1,213,787--
2025-11-18Allen James Ebens
other
2,628,787--
2025-11-18James Campbell
other
5,257,573--
2025-11-18Melanie Farris
other
2,628,787--
2025-11-18Gavin Shepherd
other
1,213,787--
2025-08-11Unknown Director
buy
---
2025-08-11Unknown Director
buy
---
2025-08-11Unknown Director
buy
---
2025-08-04James Campbell
buy
750,000$0.040$30,000

PTX intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required